Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold

On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580. REGN is one of the 7 52-week low dividend stocks to consider

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotechnology company, develops treatments in ophthalmology, oncology, and immunology. Wells Fargo’s analyst, Mohit Bansal, cited the early resubmission of the Eylea HD pre-filled syringe for FDA review, pointing toward its limited financial impact on the company. While the analyst did indicate some incremental revenue growth potential through the drug, she believes that it will get neutralized. This is evident in Eylea’s Q1 2025 performance, where U.S. sales of its older 2 mg formula fell 39%, while the newer, higher dose saw a 54% growth.

A close up photograph of a vial of a new biotechnological drug candidate in development.

The analyst further highlighted the company’s shifting growth narrative as Eylea no longer remains central to the company’s growth strategy. As such, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is shifting its focus to its broader pipeline. Although the company’s Dupixent global sales saw a YoY increase of 20% and Libtayo posted decent returns, regulatory delays continue to weigh on investor sentiment.

Thus, analysts remain cautious, with short-term headwinds countering long-term pipeline optimism.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 12 Best Gold Stocks to Invest In According to Billionaires.

Disclosure: None.